Bausch Health Cos Inc. $BHC is Goldentree Asset Management LP’s Largest Position

Goldentree Asset Management LP lifted its holdings in Bausch Health Cos Inc. (NYSE:BHC) by 1.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 34,833,431 shares of the company’s stock after purchasing an additional 578,542 shares during the period. Bausch Health Cos makes up 18.5% of Goldentree Asset Management LP’s holdings, making the stock its biggest holding. Goldentree Asset Management LP owned approximately 9.39% of Bausch Health Cos worth $224,409,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Paulson & CO. Inc. lifted its holdings in Bausch Health Cos by 24.0% during the 2nd quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after buying an additional 6,352,667 shares in the last quarter. MUFG Securities EMEA plc acquired a new position in shares of Bausch Health Cos in the second quarter worth $22,644,000. Maple Rock Capital Partners Inc. increased its position in shares of Bausch Health Cos by 14.9% during the second quarter. Maple Rock Capital Partners Inc. now owns 7,808,487 shares of the company’s stock worth $52,005,000 after acquiring an additional 1,010,987 shares during the period. Bank of America Corp DE increased its position in shares of Bausch Health Cos by 209.8% during the third quarter. Bank of America Corp DE now owns 1,447,838 shares of the company’s stock worth $9,339,000 after acquiring an additional 980,463 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Bausch Health Cos by 4.0% in the third quarter. Vanguard Group Inc. now owns 12,241,072 shares of the company’s stock valued at $78,808,000 after acquiring an additional 470,968 shares in the last quarter. 78.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BHC shares. Barclays decreased their target price on Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, February 25th. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Weiss Ratings cut Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a research note on Thursday, February 19th. Wall Street Zen downgraded Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 15th. Finally, Truist Financial upped their target price on shares of Bausch Health Cos from $7.00 to $8.00 and gave the stock a “hold” rating in a research note on Wednesday, January 7th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $8.33.

Bausch Health Cos Stock Performance

Shares of BHC stock opened at $5.10 on Thursday. The company has a market cap of $1.90 billion, a P/E ratio of 12.15 and a beta of 0.37. The firm has a fifty day moving average price of $6.04 and a 200 day moving average price of $6.49. The company has a current ratio of 1.47, a quick ratio of 1.08 and a debt-to-equity ratio of 54.68. Bausch Health Cos Inc. has a 12 month low of $4.25 and a 12 month high of $8.69.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.13). The business had revenue of $2.78 billion during the quarter, compared to analyst estimates of $2.71 billion. Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. Sell-side analysts predict that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.